U.S. Distributes Monoclonal Antibodies This Week, But Not COVID-19 Pills
The U.S. HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) today announced it was distributing 225,590 monoclonal antibody treatments but no COVID-19 oral antivirals this week.
There are four mAbs Authorized but not Approved by the U.S. FDA to treat certain patients as of January 17, 2022.
The ASPR distribution list shows the total number of patient courses that have been distributed across the country.
- Bamlanivimab/ etesevimab = 44,550
- Evusheld = 73,752
- REGEN-COV = 55,224
- Sotrovimab = 52,064
Furthermore, this week’s ASPR national allocation indicates (0) COVID-19 oral antivirals were distributed.
During the week of Jan. 11, there were 99,960 Pfizer Paxlovid, and 399,920 Merck Molnupiravir allocated to U.S. states, territories and agencies. Both Paxlovid and Molnupiravir are U.S. FDA Authorized.
Regarding the effectiveness of these mAbs and antivirals, the U.S. NIH OpenData Portal reported on January 17, 2022, in vitro Therapeutic Activity against the Omicron variant.
As of 2 pm CT on January 17, the NIH’s data indicates Sotrovimab may offer the best protection against the SARS-COV-2 virus variant known as Omicron.
As variant prevalence changes and new therapeutics become available, there are tools and resources available from the U.S. government to assist in clinical decision-making for prescribers. As an example, the U.S. HHS published an updated ‘Therapeutics Clinical Implementation Guide’ on December 29, 2021.
The latest monoclonal antibody news and information is published on this webpage.
PrecisionVaccinations publishes fact-checked research-based vaccine news.